Fluconazole (UK-49,858) treatment of candidiasis in normal and diabetic rats

M. A. Fisher, P. Gregory Lee, W. F. Tarry

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Fluconazole (UK-49,858), a new oral bistriazole antifungal agent, was compared with amphotericin B in the treatment of established systemic infection with Candida albicans in normal and diabetic rats. In normal rats, oral fluconazole at 10 mg/kg per day for 7 days reduced Candida colony counts in the kidneys and livers as well as amphotericin B did and was nearly as effective as amphotericin B in a 21-day treatment trial. There was no further reduction in Candida colony counts when normal rats were treated with fluconazole at 40 mg/kg twice a day for 7 days. In streptozotocin-induced diabetic rats, fluconazole at 20 mg/kg per day for either 7 or 21 days compared favorably with amphotericin B in efficacy. Results of our study suggest that oral fluconazole may be useful in the treatment of established disseminated candidiasis in normal as well as diabetic hosts.

Original languageEnglish (US)
Pages (from-to)1042-1045
Number of pages4
JournalAntimicrobial agents and chemotherapy
Issue number7
StatePublished - 1989
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Fluconazole (UK-49,858) treatment of candidiasis in normal and diabetic rats'. Together they form a unique fingerprint.

Cite this